MedTrace Logo

Assessment of the Effects of Chondroitin Sulphate in Patients With Knee Osteoarthritis With Functional Magnetic Resonance Imaging (fMRI)

NCT01226615 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 64

Last updated 2012-10-02

No results posted yet for this study

Summary

The main purposes of this study are:

* to determine the effects of chondroitin sulphate on brain response to pain assessed through fMRI in patients with knee osteoarthritis.
* to investigate the relationship between treatment response detected by fMRI and the results of the different parameters of clinical assessment.

Conditions

Interventions

DRUG

Chondroitin sulphate (Condrosan®)

800mg (two capsules of 400mg each) taken once a day for four months

DRUG

Placebo

Two placebo capsules taken once a day for four months.

Sponsors & Collaborators

  • Bioiberica

    lead INDUSTRY

Principal Investigators

  • Jordi Monfort, MD · Hospital del Mar

  • Jesús Pujol, MD · Hospital del Mar

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
40 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-10-31
Primary Completion
2011-10-31
Completion
2012-12-31

Countries

  • Spain

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01226615 on ClinicalTrials.gov